EACS2023: 644 Systematic literature review of real-world experience with the 2-drug regimen dolutegravir + lamivudine (DTG + 3TC) in people with HIV-1 (PWH) aged ≥50 years E. Letang , S. Di Giambenedetto , A. d’Arminio Monforte , J. Casado , A. Cabello-Úbeda , L. Hocqueloux , C. Allavena , T.J. Barber , M. Kabra , J. Priest , A. Clark , B. Jones ViiV Healthcare, Madrid, Spain, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy, San Paolo’ Hospital, University of Milan, Milan, Italy, Hospital Universitario Ramón y Cajal, Madrid, Spain, Fundación Jimenez Diaz University Hospital, Madrid, Spain, Centre Hospitalier Universitaire d’Orléans, Orléans, France, CHU Hôtel-Dieu, Nantes, France, Ian Charleson Day Centre, Royal Free London NHS Foundation Trust, London, United Kingdom, Institute for Global Health, University College London, London, United Kingdom, ViiV Healthcare, Brentford, United Kingdom, ViiV Healthcare, Durham, United States General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Despite representing >50% of PWH in Europe and North America (>20% globally), PWH aged ≥50 years are underrepresented in HIV-1 clinical studies. DTG + 3TC demonstrated high efficacy and good safety in phase 3 randomized controlled trials (RCTs), with comparable outcomes in participants aged ≥50 vs <50 years among treatment-naive (GEMINI-1/-2 at Week [W]144) and suppressed-switch populations (pooled SALSA/TANGO at W48). Supplementing RCT data from PWH aged ≥50 years with real-world evidence can help assess DTG + 3TC clinical outcomes in this understudied population. Method: A systematic literature review was conducted following PRISMA guidelines. Publications from January 2013 to March 2023 reporting DTG + 3TC data for real-world populations aged ≥50 years were obtained from Embase , Ovid MEDLINE , MEDLINE In-Process (via PubMed), and Cochrane databases and relevant conferences. Participants from a single cohort overlapping across publications were not double-counted; however, all potential overlap cannot be ruled out. Results: The literature review identified 187 publications representing 146 studies, 67 cohorts, and 36,313 PWH using DTG + 3TC; of these, 13 lead publications representing 13 unique cohorts reported baseline data and DTG + 3TC use in 1727 PWH aged ≥50 years. Five lead publications (N=833 PWH) reported outcomes for treatment-naive (n=68), treatment-experienced (n=386), and mixed naive/experienced populations (n=379). Overall, 8 studies reported DTG + 3TC effectiveness outcomes, 3 reported safety, and 4 reported tolerability. High virologic suppression rates and few virologic failures were observed across studies (Figure A). One regression analysis found no association between virologic suppression and age ≥50 years (n=36; treatment-naive). No treatment-emergent resistance mutations were reported at failure. DTG + 3TC had a good safety profile with few treatment-associated discontinuations (Figure B). Conclusions: Initial real-world studies of DTG + 3TC in PWH aged ≥50 years show high effectiveness and a safety and tolerability profile consistent with RCTs. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8,9 10 11 10 10 1 2 3 4 5 6 7 8 9 10 11 ® ® ® 141
RkJQdWJsaXNoZXIy Mzc2ODc=